Patents by Inventor Hans Briem

Hans Briem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases
    Patent number: 10266548
    Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 23, 2019
    Assignees: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Marion Hitchcock, Anne Mengel, Vera Pütter, Gerhard Siemeister, Antje Margret Wengner, Hans Briem, Knut Eis, Volker Schulze, Amaury Ernesto Fernandez-Montalvan, Stefan Prechtl, Simon Holton, Jörg Fanghänel, Philip Lienau, Cornelia Preusse, Mark Jean Gnoth
  • 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
    Patent number: 10227299
    Abstract: Compounds of formula (I) as described herein processes for their production and their use as anti-cancer agents.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: March 12, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith Graham, Ulrich Klar, Hans Briem, Gerhard Siemeister, Ursula Mönning, Jozsef Balint
  • HETEROARYLBENZIMIDAZOLE COMPOUNDS
    Publication number: 20190047980
    Abstract: The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 15, 2016
    Publication date: February 14, 2019
    Inventors: Volker SCHULZE, Tobias HEINRICH, Florian PRINZ, Julien LEFRANC, Jens SCHRÖDER, Anne MENGEL, Wilhelm BONE, Joszef BÁLINT, Antje Margret WENGNER, Knut EIS, Horst IRLBACHER, Marcus KOPPITZ, Ulf BÖMER, Benjamin BADER, Hans BRIEM, Philip LIENAU, Clara CHRIST, Detlef STÖCKIGT, Roman HILLIG
  • 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES
    Publication number: 20180256591
    Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 13, 2018
    Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
  • Substituted pyridobenzodiazepinone-derivatives and use thereof
    Patent number: 10047096
    Abstract: The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: August 14, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Schall, Jürgen Klar, Mario Lobell, Hartmut Schirok, Joachim Telser, Steffen Müller, Dirk Brohm, Hans Briem, Hannah Jörißen, Joerg Keldenich, Michael Böttger, Georges Von Degenfeld, Thomas Schlange, Ulf Bömer, Niels Lindner, Hanna Eilken, Dmitrij Hristodorov, Pierre Wasnaire, Kersten Matthias Gericke, Lars Bärfacker
  • 1H-PYRROL-3-AMINES
    Publication number: 20180222881
    Abstract: Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: August 1, 2016
    Publication date: August 9, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Gerhard SIEMEISTER, Ursula M?NNING
  • 2-(morpholin-4-yl)-1,7-naphthyridines
    Patent number: 9993484
    Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: June 12, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Lars Wortmann, Ulrich Lücking, Julien LeFranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
  • 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES
    Publication number: 20180155285
    Abstract: Compounds of formula (I) as described hereinprocesses for their production and their use as anti-cancer agents.
    Type: Application
    Filed: June 14, 2016
    Publication date: June 7, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Gerhard SIEMEISTER, Ursula MÕNNING, Jozsef BALINT
  • 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES
    Publication number: 20180016272
    Abstract: Compound of formula (I), processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: January 25, 2016
    Publication date: January 18, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Volker SCHULZE, Gerhard SIEMEISTER, Philip LIENAU, René TEMPEL, Jozsef BÁLINT
  • BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS
    Publication number: 20170305882
    Abstract: Compounds of formula (I) and their use as pharmaceuticals.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 26, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Anne MENGEL, Hans-Georg LERCHEN, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNÁNDEZ-MONTÁLVAN, Jens SCHRÖDER, Ursula MÖNNING, Simon HOLTON
  • DIAMINOHETEROARYL SUBSTITUTED INDAZOLES
    Publication number: 20170283396
    Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: March 28, 2017
    Publication date: October 5, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Christoph-Stephan HILGER, Marion HITCHCOCK, Hans BRIEM, Gerhard SIEMEISTER, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Simon HOLTON, Cornelia PREUßE, Karsten DENNER
  • SUBSTITUTED CYCLOALKENOPYRAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20170275267
    Abstract: Compounds of formula (I), processes for their production and their use as Bub1 kinase inhibitors for the treatment of hyperproliferative diseases and/or disorders responsive to induction of cell death.
    Type: Application
    Filed: March 8, 2017
    Publication date: September 28, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Marion HITCHCOCK, Christoph-Stephan HILGER, Anne MENGEL, Hans BRIEM, Simon HOLTON, Vera PÜTTER, Gerhard SIEMEISTER, Stefan PRECHTL, Amaury Ernesto FERNANDEZ-MONTALVAN, Christian STEGMANN, Cornelia PREUßE, Mark Jean GNOTH
  • BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS
    Publication number: 20170275269
    Abstract: Compounds of formula (I) and their use as pharmaceuticals.
    Type: Application
    Filed: September 17, 2015
    Publication date: September 28, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Anne MENGEL, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING
  • BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS
    Publication number: 20170273980
    Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.
    Type: Application
    Filed: September 17, 2015
    Publication date: September 28, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Anne MENGEL, Hans-Georg LERCHEN, Manfred MÖWES, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Joachim KUHNKE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING, Simon HOLTON
  • HETEROARYL SUBSTITUTED INDAZOLES
    Publication number: 20170275268
    Abstract: Compounds of formula (I), which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 28, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Marion HITCHCOCK, Anne MENGEL, Christoph-Stephan HILGER, Lars BÄRFACKER, Hans BRIEM, Gerhard SIEMEISTER, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Simon HOLTON, Cornelia PREUßE, Ursula MÖNNING
  • BENZYL SUBSTITUTED INDAZOLES
    Publication number: 20170275270
    Abstract: Compounds of formula (I) and their use as pharmaceuticals.
    Type: Application
    Filed: September 15, 2015
    Publication date: September 28, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Lars BÄRFACKER, Thomas MÜLLER, Anne MENGEL, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING
  • Substituted benzylpyrazoles
    Patent number: 9765058
    Abstract: Compounds of formula (I), and their use as pharmaceuticals.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: September 19, 2017
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Marion Hitchcock, Anne Mengel, Anja Richter, Hans Briem, Gerhard Siemeister, Wilhelm Bone, Amaury Ernesto Fernandez-Montalvan, Jens Schröder, Simon Holton, Cornelia Preuβe, Ursula Mönning
  • SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
    Publication number: 20170260198
    Abstract: Compounds of formula (1) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: February 21, 2017
    Publication date: September 14, 2017
    Applicants: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Marion HITCHCOCK, Anne MENGEL, Vera PÜTTER, Gerhard SIEMEISTER, Antje Margret WENGNER, Hans BRIEM, Knut EIS, Volker SCHULZE, Amaury Ernesto FERNANDEZ-MONTALVAN, Stefan PRECHTL, Simon HOLTON, Jörg FANGHÄNEL, Philip LIENAU, Cornelia PREUSSE, Mark Jean GNOTH
  • SUBSTITUTED PYRIDOBENZODIAZEPINONE-DERIVATIVES AND USE THEREOF
    Publication number: 20170253602
    Abstract: The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: November 23, 2015
    Publication date: September 7, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas SCHALL, Jürgen KLAR, Mario LOBELL, Hartmut SCHIROK, Joachim TELSER, Steffen MÜLLER, Dirk BROHM, Hans BRIEM, Hannah JÖRIßEN, Joerg KELDENICH (deceased), Michael BÖTTGER, Georges DEGENFELD VON, Thomas SCHLANGE, Ulf BÖMER, Niels LINDNER, Hanna EILKEN, Dmitrij HRISTODOROV, Pierre WASNAIRE, Kersten Matthias GERICKE, Lars BÄRFACKER
  • Heteroaryl substituted pyrazoles
    Patent number: 9745285
    Abstract: Compounds of formula (I), which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: August 29, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Anne Mengel, Marion Hitchcock, Anja Richter, Lars Bärfacker, Hans Briem, Gerhard Siemeister, Wilhelm Bone, Amaury Ernesto Fernandez-Montalvan, Jens Schröder, Simon Holton, Cornelia Preuβe, Ursula Mönning